In 2017, the number of class 1 new drug applications may exceed 200!

According to CPM database of China Pharmaceutical Industry Information Center, as of December 20, 2017, CDE has undertaken 199 class 1 chemicals, an increase of 42% over 2016 It is true that "explosive growth" can not be used to describe the research and development of innovative drugs in China Data source: according to the data of CPM of China Pharmaceutical Industry Information Center from 2012 to 2017, Hengrui is undoubtedly the pioneer in the research and development of innovative drugs, applying for 17 class 1 Chemicals (excluding APIs), 14 for Zhengda Tianqing and 14 for Guangdong dongyangguang, which are in the first echelon of new drug research and development Data source: CPM of China Pharmaceutical Industry Information Center In addition, we use CPM database to analyze the number of new varieties of chemicals approved for marketing from 2012 to 2017 from the perspective of "varieties approved for marketing for the first time" The new varieties here refer to the drugs that have never been marketed in China (common name + dosage form) After three consecutive years of decline from 2014 to 2016, 48 new varieties were approved for listing in 2017 as the backlog of review tasks was gradually solved To speed up the launch of new products can better meet the clinical needs of patients in China Data source: CPM of China Pharmaceutical Industry Information Center applied for these class 1 new drugs in 2017 According to the currently recognized drug treatment field, the number of anti-tumor drugs ranked first, and anti infective drugs and nervous system drugs ranked second and third respectively When these anti-tumor drugs come into the market five years later, doctor education will determine the success or failure of the enterprise's market strategy Data source: CPM of China Pharmaceutical Industry Information Center, from the perspective of applying enterprises, Zhengda Tianqing has become a big winner of new drug registration application in 2017 Among the top ten enterprises, in addition to several enterprises that you are familiar with, there is also a more mysterious enterprise - Hangzhou ruomaixing Pharmaceutical Technology Co., Ltd At present, the company has two products, rmx1001 capsule and rmx1002 tablet, which have been approved and take 216 days Data source: from the public opinion storm of "medical insurance deficit" recently broke out in CPM of China Pharmaceutical Industry Information Center, the future market prospect of innovative drugs may not be optimistic, and medical reform hopes to find a balance between meeting clinical needs and coordinating medical insurance funds In the next 5 to 10 years, after a large number of innovative drugs with similar efficacy are launched, they are likely to face a price fight, just like the bidding dilemma faced by generic drugs today.